Protective effects of Fc-fused PD-L1 on two different animal models of colitis

Gut

Volumn 64, Issue 2, 2015, Pages 260-271

  Song, Mi Young ^a   Hong, Chun Pyo ^a,b   Park, Seong Jeong ^a   Kim, Jung Hwan ^a,b   Yang, Bo Gie ^b   Park, Yunji ^a   Kim, Sae Won ^a   Kim, Kwang Soon ^b   Lee, Ji Yeung ^c   Lee, Seung Woo ^a   Jang, Myoung Ho ^b   Sung, Young Chul ^a,c  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Institute for Basic Science   (South Korea)

^c POSTECH Biotech Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; DEXTRAN SULFATE; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; GASTROINTESTINAL AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH LIGAND 1 FC CONJUGATE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; CYTOKINE; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLOGIC FACTOR; RAG-1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELL TRANSFER; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; RAG1-/- MOUSE; TH17 CELL; TREATMENT DURATION; WILD TYPE MOUSE; ACUTE DISEASE; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; COLITIS, ULCERATIVE; COLON; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE VECTOR; GENETICS; HELPER CELL; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; KNOCKOUT MOUSE; LYMPHOCYTE TRANSFUSION; METABOLISM; MUCOSAL IMMUNITY; PATHOLOGY; PROCEDURES;

ACUTE DISEASE; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD274; CELL DIFFERENTIATION; COLITIS, ULCERATIVE; COLON; CYTOKINES; DENDRITIC CELLS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENETIC VECTORS; HOMEODOMAIN PROTEINS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; LYMPHOCYTE TRANSFUSION; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TH17 CELLS;

EID: 84920873268     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307311     Document Type: Article

References (52)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
2. Solomon L, Mansor S, Mallon P, et al. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol 2010;19:235-9.
3. Hall LJ, Faivre E, Quinlan A, et al. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci 2011;56:79-89.
4. Axelsson LG, Landstrom E, Goldschmidt TJ, et al. Dextran sulfate sodium (DSS) induced experimental colitis in immunode ficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996;45:181-91.
5. Kim TW, Seo JN, Suh YH, et al. Involvement of lymphocytes in dextran sulfate sodium-induced experimental colitis. World J Gastroenterol 2006;12:302-5.
6. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev 2013;252:164-82.
7. Lindebo Holm T, Poulsen SS, Markholst H, et al. Pharmacological evaluation of the SCID T cell transfer model of colitis: as a model of Crohn's disease. Int J Inflamm 2012;2012:412178.
8. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010;24:167-82.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
10. Scherl EJ. Crohn's and colitis: treatment of 5-ASA responders and nonresponders. Gastroenterol Endoscopy News 2010;8:15-35.
11. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
12. de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101.
13. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
14. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
15. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-de ficient mice. Science 2001;291:319-22.
16. Brown KE, Freeman GJ, Wherry EJ, et al. Role of PD-1 in regulating acute infections. Curr Opin Immunol 2010;22:397-401.
17. Carter LL, Leach MW, Azoitei ML, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 2007;182:124-34.
18. Wang G, Hu P, Yang J, et al. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int 2011;31:513-19.
19. Totsuka T, Kanai T, Nemoto Y, et al. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis. Eur J Immunol 2008;38:1275-86.
20. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate infl ammatory response to sepsis. Proc Natl Acad Sci U S A 2009;106:6303-8.
21. Yao S, Wang S, Zhu Y, et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009;113:5811-18.
22. Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 2003;171:4156-63.
23. Nam HJ, Song MY, Choi DH, et al. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol 2010;40:351-8.
24. Kim DJ, Kim KS, Song MY, et al. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa. Clin Immunol 2012;144:190-9.
25. Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009;15:341-52.
26. Jang MH, Sougawa N, Tanaka T, et al. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol 2006;176:803-10.
27. Guo Z, Jang MH, Otani K, et al. CD4+CD25+ regulatory T cells in the small intestinal lamina propria show an effector/memory phenotype. Int Immunol 2008;20:307-15.
28. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203:2473-83.
29. Mikami Y, Kanai T, Sujino T, et al. Competition between colitogenic Th1 and Th17 cells contributes to the amelioration of colitis. Eur J Immunol 2010;40:2409-22.
30. Saimura M, Nagai E, Mizumoto K, et al. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther 2002;9:799-806.
31. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009;229:307-21.
32. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70.
33. Ito R, Kita M, Shin-Ya M, et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 2008;377:12-16.
34. Hayashi A, Sato T, Kamada N, et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 2013;13:711-22.
35. Hirahara K, Ghoreschi K, Yang XP, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012;36:1017-30.
36. Berndt BE, Zhang M, Chen GH, et al. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol 2007;179:6255-62.
37. Takenaka S, Safroneeva E, Xing Z, et al. Dendritic cells derived from murine colonic mucosa have unique functional and phenotypic characteristics. J Immunol 2007;178:7984-93.
38. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
39. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007;27:111-22.
40. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-101.
41. Lu L, Gambotto A, Lee WC, et al. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther 1999;6:554-63.
42. Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010;116:1291-8.
43. Luz-Crawford P, Noel D, Fernandez X, et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PloS ONE 2012;7:e45272.
44. Toh ML, Kawashima M, Hot A, et al. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis 2010;69:1562-7.
45. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006;25:309-18.
46. Berndt BE, Zhang M, Chen GH, et al. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol 2007;179:6255-62.
47. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53.
48. Krempski J, Karyampudi L, Behrens MD, et al. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011;186:6905-13.
49. Park SJ, Namkoong H, Doh J, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol 2014;95:621-9.
50. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Investig 2005;115:66-75.
51. Smith P, Mangan NE, Walsh CM, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol 2007;178:4557-66.
52. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn' s disease and ulcerative colitis. Gastroenterology 2012;143:62-9.e4.